Research Article

BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy

Figure 6

BEZ235 blocked the activation of the PI3K/mTOR pathway induced by sorafenib. (a) Sorafenib (4 μM) activated the PI3K/AKT/mTOR pathway in Huh7 and Huh7R cells. (b) BEZ235 countered the abnormal activation of the PI3K/AKT/mTOR pathway induced by sorafenib. Data are presented as , . , all versus SFB single-agent group. SFB: sorafenib; BEZ: BEZ235; SFB + BEZ: sorafenib combined with BEZ235.
(a)
(b)